<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311088</url>
  </required_header>
  <id_info>
    <org_study_id>U-2013-007</org_study_id>
    <secondary_id>2013-004412-22</secondary_id>
    <nct_id>NCT02311088</nct_id>
  </id_info>
  <brief_title>Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor</brief_title>
  <acronym>TROCADERO</acronym>
  <official_title>Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <brief_summary>
    <textblock>
      Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies&#xD;
      have implied a possible role of adenosine. The purpose of this study is to determine if the&#xD;
      caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too low enrolment rate&#xD;
  </why_stopped>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale area under the curve (VAS-AUC) for dyspnea</measure>
    <time_frame>7-10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>High on-treatment platelet reactivity by VerifyNow</measure>
    <time_frame>7-10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnea by 7-point Likert scale</measure>
    <time_frame>7-10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caffeine capsules. 200 mg twice daily orally for 7-10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules twice daily orally for 7-10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <arm_group_label>Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Recent acute coronary syndrome with ongoing ticagrelor treatment&#xD;
&#xD;
          -  Stabilized clinical condition with no plans of additional revascularization&#xD;
&#xD;
          -  Dyspnea with onset after start of ticagrelor treatment&#xD;
&#xD;
          -  Willingness to abstain from caffeine intake (e.g. coffee, tea, cola-type beverages;&#xD;
             other foods, nutritional supplements or medications containing caffeine) for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Provision of signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease, asthma or other known pulmonary disease&#xD;
             requiring daily medical therapy&#xD;
&#xD;
          -  Obstructive sleep apnea syndrome requiring therapy&#xD;
&#xD;
          -  Ongoing signs and symptoms of heart failure*, or evidence of moderately to severely&#xD;
             reduced left ventricular (LV) function&#xD;
&#xD;
          -  Renal failure, glomerular filtration rate (GFR) &lt;30 or on dialysis&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known allergy to ticagrelor, or caffeine, or known intolerance of caffeine&#xD;
&#xD;
          -  Ongoing treatment with any of the following: quinolone antibiotics, fluvoxamine,&#xD;
             phenylpropanolamine, carbamazepine, clozapine, lithium, non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs); or any drug containing theophylline or caffeine.&#xD;
&#xD;
          -  Any condition that seriously increases the risk of non-compliance or loss of follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan K James, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Cardiology, Mälarsjukhuset hospital</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Cardiology, Falu hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Östra hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Cardiology, Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Cardiology, Danderyd hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

